恶性疟原虫孢子子疫苗经直接静脉接种用于肯尼亚婴幼儿的安全性、耐受性与免疫原性
在肯尼亚西部开展年龄递减、剂量递增的双盲随机对照试验,5–12月龄至5–9岁儿童按2:1随机接受PfSPZ疫苗或生理盐水安慰剂。疫苗组与对照组主动及非主动不良事件发生率相近,无相关3级不良事件、严重不良事件或3级实验室异常;高剂量组疫苗诱导的抗PfCSP抗体阳性率显著高于安慰剂组。
要点
- 5–9岁至5–12月龄儿童经直接静脉接种PfSPZ疫苗总体安全且耐受良好。
- 未观察到相关3级不良事件、严重不良事件或3级实验室异常。
- 9.0×10^5与1.8×10^6 PfSPZ组抗PfCSP抗体阳性率80.0% vs 19.0%(P < .001)。
核心结论
- PfSPZ疫苗剂量高达1.8×10^6经直接静脉接种可用于婴幼儿和儿童,且安全、耐受良好并具有免疫原性。
研究设计与样本
- 在肯尼亚西部Siaya县开展年龄递减、剂量递增的双盲随机对照试验,儿童和婴幼儿(5–9岁、13–59个月、5–12个月)纳入13个年龄-剂量队列、每队列12人,按2:1随机接受疫苗或生理盐水安慰剂。
- 疫苗剂量递增为1.35×10^5、2.7×10^5、4.5×10^5、9.0×10^5和1.8×10^6 PfSPZ,最高两剂间隔8周各接种两次。
- 主动不良事件监测至接种后8天,非主动不良事件监测29天,严重不良事件贯穿整个研究;接种前及接种后1周采血,用酶联免疫吸附试验检测抗恶性疟原虫环子孢子蛋白(PfCSP)IgG抗体。
主要发现
- 疫苗组与对照组主动不良事件发生率分别为35.7%与41.5%,非主动不良事件分别为83.9%与92.5%。
- 未发生相关3级不良事件、严重不良事件或3级实验室异常。
- 79.0%的接种通过单次直接静脉接种完成。
- 9.0×10^5和1.8×10^6 PfSPZ组中,45名疫苗受种者中36名(80.0%)和21名安慰剂对照中4名(19.0%)产生抗PfCSP抗体(P < .001)。
临床怎么用
- 在婴幼儿和儿童中经直接静脉接种PfSPZ疫苗至1.8×10^6剂量未出现相关3级不良事件或严重不良事件,支持进一步评估该接种途径。
- 高剂量PfSPZ疫苗在婴幼儿和儿童中可诱导抗PfCSP抗体,但抗体阳性率不等同于保护效力,需以疟疾感染终点进一步验证。
局限性
- 原文未报告研究的局限性描述。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The whole Plasmodium falciparum sporozoite (PfSPZ) vaccine is being evaluated for malaria prevention. The vaccine is administered intravenously for maximal efficacy. Direct venous inoculation (DVI) with PfSPZ vaccine has been safe, tolerable, and feasible in adults, but safety data for children and infants are limited. METHODS: We conducted an age de-escalation, dose-escalation randomized controlled trial in Siaya County, western Kenya. Children and infants (aged 5-9 years, 13-59 months, and 5-12 months) were enrolled into 13 age-dose cohorts of 12 participants and randomized 2:1 to vaccine or normal saline placebo in escalating doses: 1.35 × 105, 2.7 × 105, 4.5 × 105, 9.0 × 105, and 1.8 × 106 PfSPZ, with the 2 highest doses given twice, 8 weeks apart. Solicited adverse events (AEs) were monitored for 8 days after vaccination, unsolicited AEs for 29 days, and serious AEs throughout the study. Blood taken prevaccination and 1 week postvaccination was tested for immunoglobulin G antibodies to P. falciparum circumsporozoite protein (PfCSP) using enzyme-linked immunosorbent assay. RESULTS: Rates of AEs were similar in vaccinees and controls for solicited (35.7% vs 41.5%) and unsolicited (83.9% vs 92.5%) AEs, respectively. No related grade 3 AEs, serious AEs, or grade 3 laboratory abnormalities occurred. Most (79.0%) vaccinations were administered by a single DVI. Among those in the 9.0 × 105 and 1.8 × 106 PfSPZ groups, 36 of 45 (80.0%) vaccinees and 4 of 21 (19.0%) placebo controls developed antibodies to PfCSP (P < .001). CONCLUSIONS: PfSPZ vaccine in doses as high as 1.8 × 106 can be administered to infants and children by DVI, and was safe, well tolerated, and immunogenic. CLINICAL TRIALS REGISTRATION: NCT02687373.
引用
- Steinhardt LC, Richie TL, Yego R, et al. Safety, Tolerability, and Immunogenicity of Plasmodium falciparum Sporozoite Vaccine Administered by Direct Venous Inoculation to Infants and Young Children: Findings From an Age De-escalation, Dose-Escalation, Double-blind, Randomized Controlled Study in Western Kenya. Clin Infect Dis. 2020. PMID: 31555824. doi:10.1093/cid/ciz925
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。